Business UpdateJul 8, 2026, 07:03 AM
Pasithea to Participate in B. Riley Securities Summit
AI Summary
Pasithea Therapeutics Corp. announced that its management will participate in the Mind, Muscle & Vision Summit, hosted by B. Riley Securities, on July 16, 2026. The company's management will be available for one-on-one meetings with institutional investors and other conference participants. Pasithea is a clinical-stage biotechnology company focused on developing PAS-004, a MEK inhibitor, currently in Phase 1 clinical trials for advanced cancer and Phase 1/1b trials for neurofibromatosis type 1.
Key Highlights
- Pasithea management to participate in the Mind, Muscle & Vision Summit.
- The summit is hosted by B. Riley Securities on July 16, 2026.
- Management will be available for one-on-one meetings with institutional investors.
- Company is developing PAS-004, a next-generation macrocyclic MEK inhibitor.
- PAS-004 is in Phase 1 clinical trial for advanced cancer (NCT06299839).
- PAS-004 is in Phase 1/1b clinical trial for NF1 (NCT06961565).
Price Impact
More from KTTA